Purifyze Corporation
Developer of a photosensitizer-free, reagent-free visible-light pathogen-reduction platform for platelet and plasma units. The platform uses 405 nm illumination to excite endogenous porphyrins in microbes and generate reactive oxygen species for inactivation. The company reports peer-reviewed and FDA-authored evidence across bacterial, viral, and parasitic models, device prototypes for benchtop, blood-center, and field use, and an IP and regulatory program targeting a 510(k) pathway.
Industries
N/A
Nr. of Employees
small (1-50)
Products
Single-bag benchtop pathogen-reduction unit (prototype)
Closed-system benchtop unit designed for single-bag cycles intended for hospital blood banks and research settings; supports high-intensity 405 nm LED illumination without added reagents.
Multi-bag clinical workstation (eight-bag console, prototype)
Floor-standing console sized for blood-center throughput, configured to treat multiple platelet or plasma bags per cycle without reagent addition.
Portable battery-operated field pathogen-reduction unit (prototype)
Ruggedized, battery-operated unit designed for forward deployment and austere-environment use, developed to meet military environmental standards and support prolonged field care.
MSD405-F
Ruggedized, battery-operated unit designed to MIL-STD-810H for forward deployment with the Armed Services Blood Program.
Single-bag benchtop pathogen-reduction unit (prototype)
Closed-system benchtop unit designed for single-bag cycles intended for hospital blood banks and research settings; supports high-intensity 405 nm LED illumination without added reagents.
Multi-bag clinical workstation (eight-bag console, prototype)
Floor-standing console sized for blood-center throughput, configured to treat multiple platelet or plasma bags per cycle without reagent addition.
Portable battery-operated field pathogen-reduction unit (prototype)
Ruggedized, battery-operated unit designed for forward deployment and austere-environment use, developed to meet military environmental standards and support prolonged field care.
MSD405-F
Ruggedized, battery-operated unit designed to MIL-STD-810H for forward deployment with the Armed Services Blood Program.
Services
Laboratory and in vivo testing to quantify pathogen reductions and assess product quality (e.g., platelet function tests and mouse recovery models).
Preparation for regulatory submissions and management of parallel licensing and regulatory workstreams, including planned FDA pre-submission engagement.
Laboratory and in vivo testing to quantify pathogen reductions and assess product quality (e.g., platelet function tests and mouse recovery models).
Preparation for regulatory submissions and management of parallel licensing and regulatory workstreams, including planned FDA pre-submission engagement.
Expertise Areas
- Pathogen-reduction for blood products
- Blood-component treatment (platelets and plasma)
- Device development for austere and field environments
- Clinical and product-quality validation for transfusion products
Key Technologies
- 405 nm visible-light pathogen-reduction
- Reactive oxygen species-mediated microbial inactivation
- High-intensity LED illumination arrays
- Dose-controlled illumination (J/cm², mW/cm²)
News & Updates
U.S. patent US 11,951,217 B2 issued April 2024 (co-owned by HHS/FDA as reported).
European patent EP 16784311 granted 3 June 2026 (PCT/US2016/054508; priority 2 October 2015).
Executed FDA Patent License Agreement 2026-0093-LIC, effective 12 August 2026, worldwide in field of inactivation of pathogens in blood products; license text states U.S. products 100% manufactured in the United States.
Company reports 16 FDA-authored peer-reviewed publications supporting the platform's evidence base and representative studies published in 2024–2025 describing viral, bacterial, parasitic, and product-quality outcomes.
U.S. patent US 11,951,217 B2 issued April 2024 (co-owned by HHS/FDA as reported).
European patent EP 16784311 granted 3 June 2026 (PCT/US2016/054508; priority 2 October 2015).
Executed FDA Patent License Agreement 2026-0093-LIC, effective 12 August 2026, worldwide in field of inactivation of pathogens in blood products; license text states U.S. products 100% manufactured in the United States.
Company reports 16 FDA-authored peer-reviewed publications supporting the platform's evidence base and representative studies published in 2024–2025 describing viral, bacterial, parasitic, and product-quality outcomes.